GNI Group (3G6) Price & Analysis

Compare

0 Followers

3G6 Stock Chart & Stats

€12.70

€0.40(2.20%)

At close: Jan 08 4:00 PM EST

€12.70

€0.40(2.20%)

Day’s Range― - ―

52-Week Range€8.80 - €26.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€796.30M

Enterprise Value€139.53B

Total Cash (Recent Filing)€21.10B

Total Debt (Recent Filing)€6.36B

Price to Earnings (P/E)―

Beta1.45

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.41

Shares Outstanding55,682,068

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)2.52

Price to Sales (P/S)4.71

P/FCF Ratio-46.15

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetLow debt-to-equity (~0.13 in 2025) and a conservative leverage profile give the company durable financial flexibility. This reduces refinancing risk and supports multi-quarter funding of R&D or operations, improving resilience to biotech cyclicality and execution delays.

Sustained Revenue Growth And High Gross MarginsA multi-year revenue growth trend and persistently very high gross margins indicate strong core economics and pricing power. High gross margins provide a structural buffer to absorb SG&A or R&D spend while enabling margins to recover if operating costs are reined in.

Growing Asset And Equity BaseMaterial equity and asset expansion strengthens solvency and funds strategic initiatives without immediate reliance on heavy external debt. A larger equity base improves the company's ability to invest in capex, R&D, or partnerships over the medium term.

Bears Say

Persistent Cash BurnConsecutive years of negative operating and free cash flow mean the business is not self-funding. Ongoing cash burn elevates funding risk, may force dilution or debt raises, and limits the firm's capacity to sustain R&D or commercialization without external capital.

Profitability Collapse In 2025A meaningful swing to operating and net losses in 2025 erodes earnings quality and reduces visibility into future margins. Such a sharp profitability reversal suggests structural cost or revenue issues that could persist absent clear remediation.

Volatile Earnings And Execution RiskAn extreme EPS decline (~-486%) combined with cash-flow swings from strong 2023 to negative 2024–25 indicates volatile execution. This raises the probability of uneven recovery, potential financing needs, and execution risk for long-term product or pipeline commercialization.

GNI Group News

GNI Group Swings to Non-Consolidated Loss on Absence of One-Off Gain and Forward Transaction Hit

GNI Group ( ($JP:2160) ) has issued an update. GNI Group Ltd., a biopharmaceutical company listed on the...

6d ago

GNI Group Swings to Loss in FY2025 Despite Higher Revenue and Stronger Equity Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group reported FY2025 consolidated revenue of ¥26.84 billion,...

6d ago

GNI Group Delays 2026 Earnings Forecast Amid Regulatory and Pipeline Uncertainty

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has postponed the disclosure of its full-year...

6d ago

GNI Group Explains Acquisition Plans, Earnings Revision and F351 Disclosure Strategy

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has addressed a series of investor questions...

7d ago

3G6 Earnings this Week: How Will it Perform?

GNI Group (3G6) is scheduled to report 4th quarter earnings on 02/13/2026. Regarding Q4 estimates, Wall Street analysts...

8d ago

GNI Group Slashes 2025 Profit Outlook as Cullgen Listing Is Delayed and Impairment Losses Loom

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has sharply revised its full-year 2025 consolidated...

27d ago

GNI Group Makes Dental Lab ZOO LABO a Consolidated Subsidiary to Bolster Japan Medtech Base

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has acquired all shares of dental laboratory...

1M ago

GNI Subsidiary Cullgen to Showcase Advancing Pipeline at J.P. Morgan Healthcare Conference

GNI Group ( ($JP:2160) ) has shared an update. GNI Group’s U.S.-based consolidated subsidiary Cullgen Inc. will participate...

1M ago

GNI Group’s F351 Secures Path Toward Conditional Approval and Priority Review in China

GNI Group ( ($JP:2160) ) just unveiled an update. GNI Group announced that its subsidiary Gyre Therapeutics has...

1M ago

GNI Group Exits Governance Partners ASIA Fund and Brings Key Holding On-Balance Sheet

GNI Group ( ($JP:2160) ) has issued an update. GNI Group has decided to withdraw from Governance Partners...

2M ago

3G6 FAQ

What was GNI Group Ltd.’s price range in the past 12 months?

GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.

What is GNI Group Ltd.’s market cap?

GNI Group Ltd.’s market cap is €796.30M.

When is GNI Group Ltd.’s upcoming earnings report date?

GNI Group Ltd.’s upcoming earnings report date is May 18, 2026 which is in 88 days.

How were GNI Group Ltd.’s earnings last quarter?

GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.407 earnings per share for the quarter, missing the consensus estimate of €1.229 by -€1.636.

Is GNI Group Ltd. overvalued?

According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does GNI Group Ltd. pay dividends?

GNI Group Ltd. does not currently pay dividends.

What is GNI Group Ltd.’s EPS estimate?

GNI Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GNI Group Ltd. have?

GNI Group Ltd. has 55,682,068 shares outstanding.

What happened to GNI Group Ltd.’s price movement after its last earnings report?

GNI Group Ltd. reported an EPS of -€0.407 in its last earnings report, missing expectations of €1.229. Following the earnings report the stock price went down -3.676%.

Which hedge fund is a major shareholder of GNI Group Ltd.?

Currently, no hedge funds are holding shares in DE:3G6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.